Safety and Efficacy of Human Regular U-500 Insulin Administered by Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections in Subjects With Type 2 Diabetes Mellitus: A Randomized, Open-Label, Parallel Clinical Trial
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 20 Jan 2017
At a glance
- Drugs Insulin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms VIVID
- Sponsors Eli Lilly
- 07 Jun 2017 Biomarkers information updated
- 16 Jan 2017 Planned End Date changed from 1 Apr 2017 to 1 May 2017.
- 16 Jan 2017 Planned primary completion date changed from 1 Apr 2017 to 1 May 2017.